ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. (2016)
Attributed to:
Molecular determinants of Radiosensitivity
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.radonc.2016.03.021
PubMed Identifier: 27117177
Publication URI: http://europepmc.org/abstract/MED/27117177
Type: Journal Article/Review
Volume: 119
Parent Publication: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Issue: 2
ISSN: 0167-8140